KR100236810B1 - 벤조사이클로헵텐 - Google Patents

벤조사이클로헵텐 Download PDF

Info

Publication number
KR100236810B1
KR100236810B1 KR1019940702708A KR19940702708A KR100236810B1 KR 100236810 B1 KR100236810 B1 KR 100236810B1 KR 1019940702708 A KR1019940702708 A KR 1019940702708A KR 19940702708 A KR19940702708 A KR 19940702708A KR 100236810 B1 KR100236810 B1 KR 100236810B1
Authority
KR
South Korea
Prior art keywords
formula
pyridyl
compound
group
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940702708A
Other languages
English (en)
Korean (ko)
Other versions
KR950700278A (ko
Inventor
베르델론 진-쟈쿼스
브루네트 미첼
노브레트 마르크
두르빈 필리페
구에르리에르 다니엘
니히아 루웅 트론그
Original Assignee
플레믹 크리스티안
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 플레믹 크리스티안, 메르크 파텐트 게엠베하 filed Critical 플레믹 크리스티안
Publication of KR950700278A publication Critical patent/KR950700278A/ko
Application granted granted Critical
Publication of KR100236810B1 publication Critical patent/KR100236810B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019940702708A 1992-12-07 1993-12-07 벤조사이클로헵텐 Expired - Fee Related KR100236810B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FRPV9214720 1992-12-07
FR9214720A FR2698873B1 (fr) 1992-12-07 1992-12-07 Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.
PCT/EP1993/003445 WO1994013658A2 (en) 1992-12-07 1993-12-07 Benzocycloheptenes, benzoxepines and benzothiepines

Publications (2)

Publication Number Publication Date
KR950700278A KR950700278A (ko) 1995-01-16
KR100236810B1 true KR100236810B1 (ko) 2000-02-01

Family

ID=9436308

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702708A Expired - Fee Related KR100236810B1 (ko) 1992-12-07 1993-12-07 벤조사이클로헵텐

Country Status (29)

Country Link
US (2) US5602152A (enExample)
EP (1) EP0626954B1 (enExample)
JP (1) JPH07503977A (enExample)
KR (1) KR100236810B1 (enExample)
CN (1) CN1050127C (enExample)
AT (1) ATE177742T1 (enExample)
AU (1) AU680856B2 (enExample)
CA (1) CA2129642A1 (enExample)
CZ (1) CZ184894A3 (enExample)
DE (1) DE69324001T2 (enExample)
DK (1) DK0626954T3 (enExample)
ES (1) ES2132373T3 (enExample)
FI (1) FI943646L (enExample)
FR (1) FR2698873B1 (enExample)
GR (1) GR3030514T3 (enExample)
HU (1) HUT67852A (enExample)
IL (1) IL107891A0 (enExample)
LT (1) LT3167B (enExample)
LV (1) LV10451B (enExample)
NO (1) NO942914L (enExample)
NZ (1) NZ258896A (enExample)
PL (1) PL174246B1 (enExample)
RO (1) RO113040B1 (enExample)
RU (1) RU2127268C1 (enExample)
SI (1) SI9300632A (enExample)
SK (1) SK93994A3 (enExample)
TW (1) TW276255B (enExample)
WO (1) WO1994013658A2 (enExample)
ZA (1) ZA939127B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250179805A (ko) * 2024-06-24 2025-12-31 정종기 변압기 압력조절장치

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CN1084741C (zh) * 1994-09-13 2002-05-15 孟山都公司 具有回肠胆汁酸转运和牛磺胆酸盐摄入抑制剂作用的新的苯并硫杂䓬
US5952326A (en) * 1997-12-10 1999-09-14 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
KR20010034114A (ko) * 1998-01-14 2001-04-25 니뽄 신야쿠 가부시키가이샤 칼륨 채널 활성화제
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
WO2000038726A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
EP1140190B1 (en) 1998-12-23 2002-11-20 G.D. Searle LLC. Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
PT1140187E (pt) * 1998-12-23 2004-01-30 Searle Llc Combinacoes de um inibidor de ibat e de um inibidor de mtp para indicacoes cardiovasculares
DK1140185T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
IL143949A0 (en) 1998-12-23 2002-04-21 Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
ATE240120T1 (de) * 1998-12-23 2003-05-15 Searle Llc Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
WO2000038721A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
HK1052183A1 (zh) 2000-03-10 2003-09-05 Pharmacia Corporation 制造tetrahydrobenzothiepines的方法
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
BR0306643A (pt) 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
RU2387648C1 (ru) * 2008-12-15 2010-04-27 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Способ получения алкиловых эфиров 3-оксо-1,3-дигидробензо[с]оксепин-4-карбоновой кислоты
US20140323412A1 (en) 2011-10-28 2014-10-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
SG10201909122QA (en) 2011-10-28 2019-11-28 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2834216A1 (en) 2012-04-04 2015-02-11 Catylix Inc. Selective androgen receptor modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593760A1 (de) * 1967-02-01 1972-06-08 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer Benz-epinderivate
US3444176A (en) * 1967-04-28 1969-05-13 Mcneilab Inc Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof
AU8402275A (en) * 1974-08-26 1977-02-17 Takeda Chemical Industries Ltd Benzocycloheptene derivatives
US4066663A (en) * 1976-07-01 1978-01-03 Syntex (U.S.A.) Inc. 6,11-Dihydrodibenzo-[b. e.]-thiepin-11-one-3-aldehyde and 3-acetal derivatives
ATE23718T1 (de) 1981-09-25 1986-12-15 Beecham Group Plc Benzopyran-verbindungen mit pharmazeutischer wirkung.
US4416687A (en) * 1982-02-01 1983-11-22 Monsanto Company 3,5-Bis (trifluoromethyl)phenoxy carboxylic acids and derivatives thereof
PH22343A (en) * 1983-02-15 1988-08-12 Merrell Dow Pharma 2h-(1) benzoxepino (5,4-b) 1,4-oxazine derivatives
NZ219311A (en) * 1986-02-27 1989-04-26 Janssen Pharmaceutica Nv Imidazoles and herbicidal compositions
AU597671B2 (en) * 1986-06-20 1990-06-07 Suntory Limited 2-Phenylbenzoxepin derivative
DE3726261A1 (de) 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
US4971982A (en) * 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
GB8812765D0 (en) * 1988-05-28 1988-06-29 Beecham Group Plc Novel compounds
DE3831697A1 (de) * 1988-09-17 1990-03-22 Hoechst Ag 2,3,4,5-tetrahydro-1-benzoxepine, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
DE3922392A1 (de) * 1989-07-07 1991-01-17 Merck Patent Gmbh Chromanderivate
JP3018386B2 (ja) * 1990-01-24 2000-03-13 吉富製薬株式会社 光学活性なベンゾチエピノピリダジン化合物の製造法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250179805A (ko) * 2024-06-24 2025-12-31 정종기 변압기 압력조절장치
KR102909548B1 (ko) 2024-06-24 2026-01-07 정종기 변압기 압력조절장치

Also Published As

Publication number Publication date
FR2698873A1 (fr) 1994-06-10
AU5697594A (en) 1994-07-04
US5652252A (en) 1997-07-29
KR950700278A (ko) 1995-01-16
NO942914L (no) 1994-08-05
TW276255B (enExample) 1996-05-21
RU94040853A (ru) 1996-07-10
LT3167B (en) 1995-02-27
DK0626954T3 (da) 1999-10-11
CZ184894A3 (en) 1995-02-15
AU680856B2 (en) 1997-08-14
DE69324001D1 (de) 1999-04-22
IL107891A0 (en) 1994-04-12
US5602152A (en) 1997-02-11
FR2698873B1 (fr) 1995-02-24
ES2132373T3 (es) 1999-08-16
EP0626954B1 (en) 1999-03-17
NO942914D0 (enExample) 1994-08-05
PL304719A1 (en) 1995-01-09
ZA939127B (en) 1994-08-05
LV10451B (en) 1995-12-20
DE69324001T2 (de) 1999-10-07
FI943646A7 (fi) 1994-08-05
FI943646A0 (fi) 1994-08-05
GR3030514T3 (en) 1999-10-29
SK93994A3 (en) 1995-04-12
JPH07503977A (ja) 1995-04-27
WO1994013658A2 (en) 1994-06-23
HUT67852A (en) 1995-05-29
ATE177742T1 (de) 1999-04-15
CN1050127C (zh) 2000-03-08
SI9300632A (en) 1994-09-30
CA2129642A1 (en) 1994-06-23
HU9402302D0 (en) 1994-10-28
RU2127268C1 (ru) 1999-03-10
FI943646L (fi) 1994-08-05
PL174246B1 (pl) 1998-07-31
EP0626954A1 (en) 1994-12-07
RO113040B1 (ro) 1998-03-30
LV10451A (lv) 1995-02-20
LTIP1525A (en) 1994-07-15
CN1097752A (zh) 1995-01-25
NZ258896A (en) 1996-03-26
WO1994013658A3 (en) 1994-08-04

Similar Documents

Publication Publication Date Title
KR100236810B1 (ko) 벤조사이클로헵텐
EP0691960B1 (en) Antipsychotic benzimidazole derivatives
EA002851B1 (ru) Хинолиновые и хиназолиновые соединения, применяемые в терапии, особенно при лечении доброкачественной гиперплазии простаты
JPS59181277A (ja) 新規な薬理学的に活性な化合物
JP3847786B2 (ja) 三環性化合物
US5358953A (en) Imidazopyridine PAF/H1 antagonists
US5250531A (en) Dihydropyrimidine antiallergy agents
JPH02141A (ja) 新規化合物、その製法及びそれを含む医薬組成物
EP0539154B1 (en) Acridine-1,8-dione-derivatives as therapeutic agents
JPH0471077B2 (enExample)
JPH0471914B2 (enExample)
JPH0631221B2 (ja) ジヒドロピリジン抗アレルギー剤
US4866076A (en) Biologically active compounds
EP0625511B1 (en) Heterocyclic compounds and their use in pharmaceutical
US3706747A (en) Benzothieno(3,2-d)- and benzofuro(3,2-d)pyrimidines
IE61070B1 (en) Antiarrhythmic agents
KR870001168B1 (ko) 이소인돌 유도체의 제조방법
FI89799B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 2,5-diazabicyklo/2.2.1/heptanderivat
US5079256A (en) Substituted tetrahydroisoquinoline compounds and method containing them
CA1282411C (en) 1,4,5,6,7,8-hexahydroquinoline compounds
JPS60202884A (ja) ２‐アリールイミダゾ［４，５‐ｃ］ピリジン類
KR970011277B1 (ko) 티오포름아미드 유도체

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20021006

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20021006

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000